ELI LILLY & Co LLY
Last close
1,149.36
2026-09-04
Market cap
$1.08T
2026-06-30 share count
52-week range
712.05 - 1,292.65
Valuation FY2025 figures against the last close
P/S16.6x
P/E50.1x
P/FCF64.4x
EV/EBITDA—
Dividend yield0.5%
Diluted EPS22.95
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $65.18B | $45.04B | $34.12B | $28.54B | $28.32B | $24.54B | $22.32B | $21.49B | $19.97B | $18.31B |
| Cost of revenue | $11.05B | $8.42B | $7.08B | $6.63B | $7.31B | $5.48B | $4.72B | $4.68B | $4.45B | $4.16B |
| Gross profit | $54.13B | $36.62B | $27.04B | $21.91B | $21.01B | $19.06B | $17.60B | $16.81B | $15.53B | $14.15B |
| R&D | — | — | — | $7.19B | $6.93B | $5.98B | $5.59B | $5.05B | $5.10B | $5.04B |
| SG&A | $11.09B | $8.59B | $7.40B | $6.44B | $6.43B | $6.12B | $6.21B | $5.98B | $5.98B | $5.84B |
| Interest expense | $895.0M | $781.0M | $486.0M | $331.6M | $339.8M | $359.6M | $400.6M | $242.5M | $225.0M | $185.2M |
| Pre-tax income | $25.73B | $12.68B | $6.55B | $6.81B | $6.16B | $7.23B | $5.27B | $3.68B | $2.30B | $3.28B |
| Income tax | $5.09B | $2.09B | $1.31B | $561.6M | $573.8M | $1.04B | $628.0M | $529.5M | $2.39B | $551.4M |
| Net income | $20.64B | $10.59B | $5.24B | $6.24B | $5.58B | $6.19B | $8.32B | $3.23B | -$204.1M | $2.74B |
| EPS, basic | 23.00 | 11.76 | 5.82 | 6.93 | 6.15 | 6.82 | 8.93 | 3.14 | -0.19 | 2.59 |
| EPS, diluted | 22.95 | 11.71 | 5.80 | 6.90 | 6.12 | 6.79 | 8.89 | 3.13 | -0.19 | 2.58 |
| Shares, diluted (wtd. avg.) | $899.3M | $904.1M | $903.3M | $904.6M | $911.7M | $912.5M | $935.7M | $1.03B | $1.05B | $1.06B |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $7.27B | $3.27B | $2.82B | $2.07B | $3.82B | $3.66B | $2.34B | $7.32B | $6.21B | $4.58B |
| Short-term investments | — | $154.8M | $109.1M | $144.8M | $90.1M | $24.2M | $101.0M | $88.2M | $1.50B | $1.46B |
| Receivables | $17.76B | $11.01B | $9.09B | $6.90B | $6.67B | $5.88B | $4.55B | $4.59B | $3.98B | $4.03B |
| Inventory | $13.74B | $7.59B | $5.77B | $4.31B | $3.89B | $3.98B | $3.19B | $3.10B | $3.40B | $3.56B |
| Total current assets | $55.63B | $32.74B | $25.73B | $18.03B | $18.45B | $17.46B | $13.71B | $20.55B | $19.20B | $15.10B |
| Property, plant and equipment | $24.68B | $17.10B | $12.91B | $10.14B | $8.99B | $8.68B | $7.87B | $8.00B | $7.89B | $8.25B |
| Goodwill | $5.90B | $5.77B | $4.94B | $4.07B | $3.89B | $3.77B | $3.68B | $1.37B | $1.38B | $3.97B |
| Other intangibles | $6.52B | $6.17B | $6.91B | $7.21B | $7.69B | $7.45B | $6.62B | $1.07B | $1.35B | $4.36B |
| Total assets | $112.48B | $78.72B | $64.01B | $49.49B | $48.81B | $46.63B | $39.29B | $43.91B | $44.98B | $38.81B |
| Accounts payable | $5.38B | $3.23B | $2.60B | $1.93B | $1.67B | $1.61B | $1.41B | $1.21B | $1.21B | $1.35B |
| Short-term debt | $1.64B | $5.12B | $6.90B | $1.50B | $1.54B | $8.7M | $1.50B | $1.10B | $3.71B | $1.94B |
| Total current liabilities | $35.23B | $28.38B | $27.29B | $17.14B | $15.05B | $12.48B | $11.78B | $11.89B | $14.54B | $10.99B |
| Long-term debt | $40.87B | $28.53B | $18.32B | $14.74B | $15.35B | $16.59B | $13.82B | $9.20B | $9.94B | $8.37B |
| Retained earnings | $24.47B | $13.54B | $10.31B | $10.04B | $8.96B | $7.83B | $4.92B | $11.40B | $13.89B | $16.05B |
| Total equity | $26.54B | $14.27B | $10.77B | $10.65B | $8.98B | $5.64B | $2.61B | $9.83B | $11.59B | $14.01B |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $16.81B | $8.82B | $4.24B | $7.59B | $7.37B | $6.50B | $4.84B | $5.52B | $5.62B | $4.85B |
| Depreciation and amortisation | $2.00B | $1.77B | $1.53B | $1.52B | $1.55B | $1.32B | $1.23B | $1.61B | $1.57B | $1.50B |
| Stock-based compensation | $626.0M | $646.0M | $629.0M | $371.1M | $342.8M | $308.1M | $312.4M | $279.5M | $281.3M | $255.3M |
| Investing cash flow | -$10.97B | -$9.30B | -$7.15B | -$3.76B | -$2.87B | -$2.26B | -$8.08B | $1.91B | -$3.78B | -$3.14B |
| Financing cash flow | -$2.21B | $1.23B | $3.50B | -$5.41B | -$4.13B | -$3.14B | -$2.32B | -$5.90B | $142.6M | -$559.8M |
| Dividends paid | $5.38B | $4.68B | $4.07B | $3.54B | $3.09B | $2.69B | $2.41B | $2.31B | $2.19B | $2.16B |
| Buybacks | $4.11B | $2.50B | $750.0M | $1.50B | $1.25B | $500.0M | $4.40B | $4.15B | $299.8M | $600.1M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0000059478-26-000013.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $138.42B | 35.6x | 8.9% |